Evaluate the Safety and Efficacy of BLEX 404 Oral Liquid Combined With Pemetrexed + Cisplatin Therapy

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 1, 2026

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions

Nonsquamous Nonsmall Cell Neoplasm of Lung

Interventions

DRUG

BLEX 404

BLEX 404 Oral Liquid, PO, BID

Trial Locations (1)

Taipei Veteran General Hospital, Taipei

All Listed Sponsors

collaborator

American BriVision Corporation

UNKNOWN

lead

Rgene Corporation

INDUSTRY

NCT05764928 - Evaluate the Safety and Efficacy of BLEX 404 Oral Liquid Combined With Pemetrexed + Cisplatin Therapy | Biotech Hunter | Biotech Hunter